Home・Aandelen Lijst・Tandem Diabetes Care Inc

Tandem Diabetes Care Inc

Gesloten

SectorGezondheidszorg

22.7 -1.52

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

22.35

Max

22.78

Belangrijke statistieken
By Trading Economics
Inkomsten	-775K -21M
Verkoop	7.3M 255M
EPS	-0.31
Winstmarge	-8.316
Werknemers	2,500
EBITDA	4.5M -9.2M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+16.64% upside

Dividenden
By Acuity
Volgende Winsten	5 nov 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	209M 1.6B
Vorige openingsprijs	24.22
Vorige sluitingsprijs	22.7

Nieuwssentiment

By Acuity

50%

142 / 340 Rangschikking in Healthcare

Tandem Diabetes Care Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 aug 2026, 20:06 UTC

Tandem Diabetes Care shares are lower today amid economic concerns following a disappointing U.S. retail sales report for July. The stock remains above its 20-day moving average.

13 aug 2026, 19:16 UTC

Tandem Diabetes Care shares are trading lower today, despite broader market support and an early high. Initial jobless claims rose, indicating potential labor market softening.

12 aug 2026, 19:41 UTC

News

Tandem Diabetes Care reported a narrower second-quarter loss of 31 cents per share, with revenues of $254.6 million, as shares rise since Tuesday.

11 aug 2026, 19:46 UTC

News

Tandem Diabetes Care reported improved second-quarter results, including a narrower loss and increased revenue, supporting shares' advance during Tuesday's session.

10 aug 2026, 19:36 UTC

News

Tandem Diabetes Care reported second-quarter revenue of $254.6 million and reaffirmed its full-year guidance of $1.08 billion, supporting a higher share price today.

7 aug 2026, 20:02 UTC

News

Tandem Diabetes Care shares rose after Q2 sales of $254.6 million and adjusted EBITDA of $6.4 million exceeded forecasts, despite RBC lowering its price target to $26.

6 aug 2026, 23:02 UTC

News

Tandem Diabetes Care reported Q2 sales of $254.6 million and reaffirmed revenue guidance, with shares trading higher in after-market hours.

5 aug 2026, 19:56 UTC

News

Tandem Diabetes Care Inc's shares are declining amid negative sentiment in the insulin sector following Insulet Corp's lowered revenue growth forecast.

4 aug 2026, 19:46 UTC

Tandem Diabetes Care Inc shares are lower today, influenced by declines in the Health Care Equipment sub-sector. Earlier, the stock reached a session high before pulling back.

31 jul 2026, 19:51 UTC

Tandem Diabetes Care Inc is advancing today, benefiting from positive market sentiment driven by technology stocks, despite pulling back from earlier session highs.

30 jul 2026, 17:11 UTC

Tandem Diabetes Care shares are lower today as the Health Care Equipment sub-sector declines. The asset remains above its 20-day moving average.

29 jul 2026, 18:15 UTC

Tandem Diabetes Care Inc. shares are higher, driven by significant gains in Health Care Equipment stocks, despite a recent trend of daily price increases.

27 jul 2026, 19:21 UTC

Tandem Diabetes Care Inc. shares are lower, reflecting broader market trends amid declining oil prices and easing geopolitical tensions ahead of the Federal Reserve meeting.

24 jul 2026, 14:02 UTC

Tandem Diabetes Care Inc shares are lower today, with no specific news identified. Broader market concerns follow a significant sell-off on Thursday.

21 jul 2026, 19:06 UTC

Tandem Diabetes Care is lower today, driven by declines in the Health Care Equipment sub-sector. The asset has fallen steadily after an early high.

20 jul 2026, 17:26 UTC

Tandem Diabetes Care Inc shares are higher today, recovering from an early dip. The stock has gained significantly since last month’s close.

Peer Vergelijking

Prijswijziging

Tandem Diabetes Care Inc Prognose

Koersdoel

By TipRanks

16.64% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 26.5 USD 16.64%

Hoogste 50 USD

Laagste 15.5 USD

Gebaseerd op 15 Wall Street-analisten die 12-maands prijsdoelen bieden voor Tandem Diabetes Care Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

15 ratings

Buy

Hold

Sell

Gebaseerd op 15 analisten die aandelenratings hebben gegeven aan Tandem Diabetes Care Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

142 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Tandem Diabetes Care Inc

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. It has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.